Publications
PUBLICATIONS
- Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot, Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands, Value in Health, 2024,
https://doi.org/10.1016/j.jval.2024.06.003 - Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, et al. (2024) Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. PLOS ONE 19(2): e0293264. https://doi.org/10.1371/journal.pone.0293264
POSTER
- Salcher-Konrad M, Hendrickx A, Schneider P, Zimmermann N. Defining fair prices for new health technologies. 5th PPRI conference 2024: Ensuring access to affordable medicines through innovative policies, Vienna, 25–26 April 2024
- Salcher-Konrad M, Zimmermann N, Schneider P, Hendrickx A: What is a fair price? A review of definitions for fair prices of health technologies. ISPOR Europe 2023, Copenhagen, 14 November 2023
press releases
Contact
Please get in touch with us if you have any questions or comments! We will get back to you as soon as possible.
For research-related questions:
Carin Uyl-de Groot
Project Coordinator
Erasmus University Rotterdam
ln.rue.mphse@lyu
Phone: +31 10 4081583
For general project questions:
Marcel Langone Marques
Project Manager
Erasmus University Rotterdam
ln.rue@seuqramenognal.lecram
Phone: +31 10 4081583
For communications:
Lena Jessen
Project Manager
OptiMedis
ed.sidemitpo@nessej.l
Phone: +49 40 226211490